Related Experiment Video

Updated: Dec 12, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells

Wen-Qi Cai1,2, Li-Si Zeng3, Li-Feng Wang4

  • 1Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, China.

Frontiers in Oncology
|August 15, 2020
PubMed

Insights

This review details Epidermal Growth Factor Receptor (EGFR) monoclonal antibodies, their mechanisms, and clinical trials. It also re-classifies resistance mechanisms and discusses strategies to overcome them for durable anti-tumor effects.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Epidermal Growth Factor Receptor (EGFR) is crucial in epithelial cancers.
  • Targeting EGFR with monoclonal antibodies is a key strategy in precision medicine.
  • Several EGFR monoclonal antibodies are approved, with more in clinical development.

Purpose of the Study:

  • To comprehensively review biological properties and anti-tumor mechanisms of EGFR monoclonal antibodies.
  • To summarize clinical trial data for existing and novel EGFR monoclonal antibodies.
  • To re-classify tumor cell resistance mechanisms and discuss overcoming strategies.

Main Methods:

  • Literature review of biological properties and anti-tumor mechanisms.
  • Summary of completed and ongoing clinical trials.
  • Re-classification of resistance mechanisms based on a new standard.

Main Results:

  • Detailed overview of EGFR monoclonal antibody functions and therapeutic potential.
  • Compilation of clinical efficacy and safety data from various trials.
  • Identification and categorization of complex resistance mechanisms, including exosome, non-coding RNA, and tumor microenvironment involvement.

Conclusions:

  • EGFR monoclonal antibodies represent a significant advance in cancer therapy.
  • Understanding evolving resistance mechanisms is critical for improving treatment outcomes.
  • Future research should focus on developing antibodies with durable efficacy against resistant tumors.
Keywords:
epidermal growth factor receptorexosomesmonoclonal antibodiesnon-coding RNAresistancetumor microenvironment

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K